keyword
MENU ▼
Read by QxMD icon Read
search

Temsirolimus trial

keyword
https://www.readbyqxmd.com/read/27893038/targeting-the-pi3k-akt-mtor-pathway-for-the-treatment-of-mesenchymal-triple-negative-breast-cancer-evidence-from-a-phase-1-trial-of-mtor-inhibition-in-combination-with-liposomal-doxorubicin-and-bevacizumab
#1
Reva K Basho, Michael Gilcrease, Rashmi K Murthy, Thorunn Helgason, Daniel D Karp, Funda Meric-Bernstam, Kenneth R Hess, Shelley M Herbrich, Vicente Valero, Constance Albarracin, Jennifer K Litton, Mariana Chavez-MacGregor, Nuhad K Ibrahim, James L Murray, Kimberly B Koenig, David Hong, Vivek Subbiah, Razelle Kurzrock, Filip Janku, Stacy L Moulder
Importance: Triple-negative breast cancer (TNBC) classified by transcriptional profiling as the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (PI3K) pathway, raising the possibility of targeting this pathway to enhance chemotherapy response. Up to 30% of mesenchymal TNBC can be classified histologically as metaplastic breast cancer, a chemorefractory group of tumors with a mixture of epithelial and mesenchymal components identifiable by light microscopy...
November 23, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27793908/co-treatment-of-ly294002-or-mk-2206-with-azd5363-attenuates-azd5363-induced-increase-in-the-level-of-phosphorylated-akt
#2
Ae-Ran Choi, Ju-Hwa Kim, Yeon Hwa Woo, Ji Hyun Cheon, Hyung Sik Kim, Sungpil Yoon
Clinical trials are in progress on AZD5363, an inhibitor of protein kinase B (AKT), to assess its effects on the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway. Cells treated with AKT inhibitors have been reported to activate alternative pathways in order to escape growth inhibition. AZD5363-sensitized Hs578T breast cancer cells displayed reduced levels of phosphorylated glycogen synthase kinase 3 beta (pGSK3β). Interestingly, in AZD5363-treated cells, the level of phosphorylated (activated) AKT (pAKT) increased...
November 2016: Anticancer Research
https://www.readbyqxmd.com/read/27791402/attributable-risk-of-infection-to-mtor-inhibitors-everolimus-and-temsirolimus-in-the-treatment-of-cancer
#3
Christine A Garcia, Shenhong Wu
The risk of infection attributable to mTOR inhibitors has not been determined. Databases from PubMed and abstracts presented at the American Society of Clinical Oncology meetings were searched. Eligible studies included randomized controlled trials, in which everolimus or temsirolimus was compared with placebo. A total of 12 trials were included. The attributable incidences of all-grade and high-grade infections to mTOR inhibitors were 9.3% (95% confidence interval (CI): 5.8-14.6%) and 2.3% (95% CI: 1.2-4.4%) respectively...
October 28, 2016: Cancer Investigation
https://www.readbyqxmd.com/read/27741505/wide-spetcrum-mutational-analysis-of-metastatic-renal-cell-cancer-a-retrospective-next-generation-sequencing-approach
#4
Michelangelo Fiorentino, Elisa Gruppioni, Francesco Massari, Francesca Giunchi, Annalisa Altimari, Chiara Ciccarese, Davide Bimbatti, Aldo Scarpa, Roberto Iacovelli, Camillo Porta, Sarhadi Virinder, Giampaolo Tortora, Walter Artibani, Riccardo Schiavina, Andrea Ardizzoni, Matteo Brunelli, Sakari Knuutila, Guido Martignoni
Renal cell cancer (RCC) is characterized by histological and molecular heterogeneity that may account for variable response to targeted therapies. We evaluated retrospectively with a next generation sequencing (NGS) approach using a pre-designed cancer panel the mutation burden of 32 lesions from 22 metastatic RCC patients treated with at least one tyrosine kinase or mTOR inhibitor. We identified mutations in the VHL, PTEN, JAK3, MET, ERBB4, APC, CDKN2A, FGFR3, EGFR, RB1, TP53 genes. Somatic alterations were correlated with response to therapy...
October 10, 2016: Oncotarget
https://www.readbyqxmd.com/read/27721266/a-comparison-of-drug-resistances-of-targeted-drugs-for-advanced-renal-cell-cancer-approved-by-the-food-and-drug-administration-a-meta-analysis-of-randomized-clinical-trials
#5
Ming Guo, Yunsong Cao, Jingzhe Yang, Jingfeng Zhang
PURPOSE: The purpose of this study was to conduct network meta-analysis to assess drug resistances of the Food and Drug Administration-approved drugs for advanced renal cell carcinoma. MATERIALS AND METHODS: Database searches were conducted to identify randomized controlled trials reporting results for eligible treatments. After searching for PubMed, MEDLINE, EMBASE, and ISI Web of Science, 22 studies (n = 7854 patients) were included for the comparison of drug resistance in the present meta-analysis...
October 2016: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/27714772/mammalian-target-of-rapamycin-inhibition-with-temsirolimus-in-myelodysplastic-syndromes-mds-patients-is-associated-with-considerable-toxicity-results-of-the-temsirolimus-pilot-trial-by-the-german-mds-study-group-d-mds
#6
Martin Wermke, Claudia Schuster, Florian Nolte, Haifa-Kathrin Al-Ali, Philipp Kiewe, Claudia Schönefeldt, Christiane Jakob, Malte von Bonin, Leopold Hentschel, Ina-Maria Klut, Gerhard Ehninger, Martin Bornhäuser, Gustavo Baretton, Ulrich Germing, Regina Herbst, Detelef Haase, Wolf K Hofmann, Uwe Platzbecker
The mammalian-target of rapamycin (also termed mechanistic target of rapamycin, mTOR) pathway integrates various pro-proliferative and anti-apoptotic stimuli and is involved in regulatory T-cell (TREG) development. As these processes contribute to the pathogenesis of myelodysplastic syndromes (MDS), we hypothesized that mTOR modulation with temsirolimus (TEM) might show activity in MDS. This prospective multicentre trial enrolled lower and higher risk MDS patients, provided that they were transfusion-dependent/neutropenic or relapsed/refractory to 5-azacitidine, respectively...
October 7, 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/27664394/improvement-in-survival-end-points-of-patients-with-metastatic-renal-cell-carcinoma-through-sequential-targeted-therapy
#7
Emiliano Calvo, Manuela Schmidinger, Daniel Y C Heng, Viktor Grünwald, Bernard Escudier
Survival of patients with metastatic renal cell carcinoma (mRCC) has improved since the advent of targeted therapy. Approved agents include the multi-targeted tyrosine kinase inhibitors (TKIs) sunitinib, sorafenib, axitinib, pazopanib, cabozantinib, and lenvatinib (approved in combination with everolimus), the anti-VEGF monoclonal antibody bevacizumab, the mammalian target of rapamycin (mTOR) inhibitors everolimus and temsirolimus, and the programmed death-1 (PD-1) targeted immune checkpoint inhibitor nivolumab...
September 10, 2016: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/27453754/metastatic-clear-cell-renal-carcinoma-an-unusual-response-to-temsirolimus-in-second-line-therapy
#8
D L Stanculeanu, A Lazescu, D D Zob, R Bunghez, R Anghel, T D Poteca
Renal cell carcinoma (RCC) represents 3% of all cancers, with the highest incidence occurring in the most developed countries and representing the seventh most common cancer in men and the ninth most common cancer in women. The understanding of the tumor molecular biology and the discovery of new drugs that target molecular pathways have increased the arsenal against advanced renal cell carcinoma and improved the outcomes in the patients suffering from these affections. Studying the molecular signaling that controls the tumor growth and the progression has led to the development of molecular therapies targeting the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways, resulting in a significant improvement in the overall survival and quality of life...
April 2016: Journal of Medicine and Life
https://www.readbyqxmd.com/read/27338360/role-of-mtor-inhibitors-in-kidney-disease
#9
REVIEW
Moto Kajiwara, Satohiro Masuda
The first compound that inhibited the mammalian target of rapamycin (mTOR), sirolimus (rapamycin) was discovered in the 1970s as a soil bacterium metabolite collected on Easter Island (Rapa Nui). Because sirolimus showed antiproliferative activity, researchers investigated its molecular target and identified the TOR1 and TOR2. The mTOR consists of mTOR complex 1 (mTORC1) and mTORC2. Rapalogues including sirolimus, everolimus, and temsirolimus exert their effect mainly on mTORC1, whereas their inhibitory effect on mTORC2 is mild...
2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27324136/pazopanib-versus-sunitinib-for-the-treatment-of-metastatic-renal-cell-carcinoma-patients-with-poor-risk-features
#10
Jwa Hoon Kim, Inkeun Park, Jae Lyun Lee
PURPOSE: With the exception of temsirolimus, clinical trials in metastatic renal cell carcinoma (mRCC) with poor-risk features are lacking. We previously showed that vascular endothelial growth factor receptor tyrosine kinase inhibitors are active and well tolerated by poor-risk group. This study evaluated and compared the efficacy and safety of pazopanib and sunitinib in this group. METHODS: We reviewed the medical records of all patients with mRCC who had received pazopanib or sunitinib at Asan Medical Center...
August 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/27238653/early-tumour-shrinkage-a-tool-for-the-detection-of-early-clinical-activity-in-metastatic-renal-cell-carcinoma
#11
Viktor Grünwald, Xun Lin, Daniel Kalanovic, Ronit Simantov
BACKGROUND: The predictive role of objective remission remains undefined for targeted agents in metastatic renal cell carcinoma (mRCC); however, early tumour shrinkage (eTS) was shown to be predictive and/or prognostic for overall survival (OS) and progression-free survival (PFS) in mRCC in several small studies. OBJECTIVE: To evaluate the degree of eTS following systemic therapy that may predict survival in mRCC. DESIGN, SETTING, AND PARTICIPANTS: Data from 4334 patients with mRCC in phase 2 and 3 clinical trials between 2003 and 2013 were pooled for analyses...
May 26, 2016: European Urology
https://www.readbyqxmd.com/read/27231799/real-world-axitinib-use-in-the-united-states-a-retrospective-study-using-linked-datasets
#12
Elizabeth MacLean, Laura Cisar, Kimberly Mehle, Daria Eremina, Jane M Quigley
BACKGROUND: Axitinib is approved by the FDA for the treatment of advanced renal cell carcinoma (RCC) after failure of 1 previous systemic therapy and is distributed primarily through specialty pharmacies. Although the efficacy and safety of axitinib have been established in clinical trials, information from real-world populations will help to elucidate patients' clinical profiles and utilization patterns. Prescription records alone provide limited information on patient characteristics and other treatment experiences...
June 2016: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27034725/the-role-of-neoadjuvant-therapy-in-the-management-of-locally-advanced-renal-cell-carcinoma
#13
REVIEW
Leonardo D Borregales, Mehrad Adibi, Arun Z Thomas, Christopher G Wood, Jose A Karam
In the past decade, the armamentarium of targeted therapy agents for the treatment of metastatic renal cell carcinoma (RCC) has significantly increased. Improvements in response rates and survival, with more manageable side effects compared with interleukin 2/interferon immunotherapy, have been reported with the use of targeted therapy agents, including vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors (sunitinib, sorafenib, pazopanib, axitinib), mammalian target of rapamycin (mTOR) inhibitors (everolimus and temsirolimus) and VEGF receptor antibodies (bevacizumab)...
April 2016: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/27014780/phase-i-dose-escalation-study-of-temsirolimus-in-combination-with-metformin-in-patients-with-advanced-refractory-cancers
#14
Muhammad R Khawaja, Alpa M Nick, Vinu Madhusudanannair, Siqing Fu, David Hong, Lacey M McQuinn, Chaan S Ng, Sarina A Piha-Paul, Filip Janku, Vivek Subbiah, Apostolia Tsimberidou, Daniel Karp, Funda Meric-Bernstam, Karen H Lu, Aung Naing
PURPOSE: Mammalian target of rapamycin (mTOR) inhibitors like temsirolimus may result in undesirable AKT upregulation. Metformin inhibits mTOR through different mechanisms and may enhance temsirolimus's antitumor activity. We conducted an open-label phase I dose escalation trial of this drug combination in patients with advanced/refractory cancers. METHODS: Temsirolimus, 25 mg weekly, was combined with an escalating daily dose of metformin (level 1: 500; level 2: 1000; level 3: 1500; level 4: 2000 mg) by utilizing a standard 3 + 3 trial design...
May 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/26976424/phase-ii-trial-of-temsirolimus-for-relapsed-refractory-primary-cns-lymphoma
#15
Agnieszka Korfel, Uwe Schlegel, Ulrich Herrlinger, Martin Dreyling, Christian Schmidt, Luisa von Baumgarten, Antonio Pezzutto, Thomas Grobosch, Sied Kebir, Eckhard Thiel, Peter Martus, Philipp Kiewe
PURPOSE: In this phase II study (NCT00942747), temsirolimus was tested in patients with relapsed or refractory primary CNS lymphoma (PCNSL). PATIENTS AND METHODS: Immunocompetent adults with histologically confirmed PCNSL after experiencing high-dose methotrexate-based chemotherapy failure who were not eligible for or had experienced high-dose chemotherapy with autologous stem-cell transplant failure were included. The first cohort (n = 6) received 25 mg temsirolimus intravenously once per week...
May 20, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/26945986/first-line-treatments-for-poor-prognosis-metastatic-renal-cell-carcinoma-experts-prescribing-practices-and-systematic-literature-review
#16
Olivia Le Saux, Gilles Freyer, Sylvie Négrier
BACKGROUND AND OBJECTIVES: No head-to-head clinical trials are available to help physicians in the decision-making process of first-line therapy in poor-prognosis metastatic renal cell carcinoma (RCC). The objectives of our study were to identify experts' prescribing practices and to review available clinical data in first-line therapies for poor-prognosis metastatic RCC (mRCC). METHODS: Thirteen RCC experts were asked to fill in a self-administered questionnaire evaluating prescribing practices...
May 2016: Clinical Drug Investigation
https://www.readbyqxmd.com/read/26908232/adverse-reactions-in-mrcc-patients-documented-in-routine-practice-by-german-office-based-oncologists-and-uro-oncologists
#17
Norbert Marschner, Lothar Müller, Axel Münch, Klaus Blumenstengel, Ulrich Hutzschenreuter, Sabine Busies
BACKGROUND: Signal transduction inhibitors (STIs) have considerably improved treatment of advanced/metastasized renal cell carcinoma (mRCC). Most safety data for these drugs are derived from clinical trials. The purpose of this study was to evaluate which adverse drug reactions are documented during first-line treatments in routine clinical practice. PATIENTS AND METHODS: The ongoing prospective German mRCC clinical registry is recruiting patients in 110 oncology and urology outpatient centers...
February 22, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/26886710/-current-therapeutic-strategies-for-mantle-cell-lymphoma
#18
M Dreyling, A Schnaiter, C Schmidt, E Hoster
Mantle cell lymphoma is a subtype of B‑cell lymphoma with a mostly aggressive behavior and poor long-term prognosis. The choice of therapy depends on the age, performance status and risk profile of the patient. Randomized trials have confirmed the superiority of a dose-intensified induction therapy containing cytarabine followed by autologous stem cell transplantation in the first-line treatment of younger patients with a good general condition. Elderly patients benefit from a rituximab maintenance therapy after immunochemotherapy...
March 2016: Der Internist
https://www.readbyqxmd.com/read/26886011/first-line-therapy-for-treatment-naive-patients-with-advanced-metastatic-renal-cell-carcinoma-a-systematic-review-of-published-randomized-controlled-trials
#19
REVIEW
Shweta Takyar, Jose Diaz, Manu Sehgal, Francisco Sapunar, Hardev Pandha
In the recent years, a number of targeted therapies have been approved for first-line treatment of patients with metastatic renal cell carcinoma. A systematic review was conducted to assess the clinical efficacy, safety and effect of all first-line treatments evaluated to date on health-related quality of life (HRQoL). A systematic search of Embase, Cochrane and MEDLINE databases was performed to identify randomized controlled trials (1980-2015) evaluating any targeted therapy/immunotherapy against placebo or any other targeted intervention/immunotherapy in treatment-naive patients with metastatic renal cell carcinoma...
June 2016: Anti-cancer Drugs
https://www.readbyqxmd.com/read/26816832/sequence-of-treatment-in-locally-advanced-and-metastatic-renal-cell-carcinoma
#20
REVIEW
Stefanie Fischer, Silke Gillessen, Christian Rothermundt
The spectrum of drugs that have shown activity in advanced or metastatic renal cell carcinoma (RCC) has led to a debate on the optimal sequence of treatments. There is agreement on recommending targeted agents as the standard of care in this disease. Uncertainty, however, remains on the best first-line drug choice. Physicians and patients may select sunitinib, bevacizumab in combination with interferon-alpha (IFN-α), pazopanib, or-in poor risk patients-temsirolimus. There are also a variety of therapies with proven efficacy on hand in the second-line setting: sorafenib, pazopanib, axitinib, and everolimus...
June 2015: Translational Andrology and Urology
keyword
keyword
66684
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"